Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Ou, Da Liang ^a,b   Lee, Bin Shyun ^b   Chang, Ya Chi ^b   Lin, Liang In ^a   Liou, Jun Yang ^c   Hsu, Chiun ^b   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; NVP AEW 541; PROTEIN KINASE B; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; SORAFENIB; SUNITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; CHECKPOINT KINASE 2; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; INDOLES; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879266004     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066589     Document Type: Article

References (42)

1. Shen YC, Hsu C, Cheng AL, (2010) Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 45: 794-807.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
4. Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, et al. (2009) Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. Clin Cancer Res 15: 5820-5828.
5. Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, et al. (2011) Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol 55: 1041-1048.
6. Llovet JM, Bruix J, (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327.
7. Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, et al. (2010) IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 52: 550-559.
8. Caro JF, Poulos J, Ittoop O, Pories WJ, Flickinger EG, et al. (1988) Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest 81: 976-981.
9. Scharf JG, Schmidt-Sandte W, Pahernik SA, Ramadori G, Braulke T, et al. (1998) Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC). Carcinogenesis 19: 2121-2128.
10. Tsai TF, Yauk YK, Chou CK, Ting LP, Chang C, et al. (1988) Evidence of autocrine regulation in human hepatoma cell lines. Biochem Biophys Res Commun 153: 39-45.
11. Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, et al. (2008) Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 48: 146-156.
12. Kim SO, Park JG, Lee YI, (1996) Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res 56: 3831-3836.
13. Lee YI, Lee S, Lee Y, Bong YS, Hyun SW, et al. (1998) The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter 4. Oncogene 16: 2367-2380.
14. Lee YI, Lee S, Das GC, Park US, Park SM, (2000) Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma. Oncogene 19: 3717-3726.
15. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE, (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21: 215-244.
16. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, et al. (2004) Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11: 793-814.
17. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M, (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852-1857.
18. Sell C, Baserga R, Rubin R, (1995) Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 55: 303-306.
19. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, et al. (2003) An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63: 5073-5083.
20. Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D, (2004) A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 279: 5017-5024.
21. Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, et al. (2005) A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113: 316-328.
22. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, et al. (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5: 221-230.
23. Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A, (2004) An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 68: 1003-1015.
24. Yao X, Hu JF, Daniels M, Yien H, Lu H, et al. (2003) A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clin Cancer Res 9: 2719-2726.
25. Lee OH, Bae SK, Bae MH, Lee YM, Moon EJ, et al. (2000) Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models. Br J Cancer 82: 385-391.
26. Gao J, Chang YS, Jallal B, Viner J, (2012) Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res 72: 3-12.
27. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, et al. (2004) In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5: 231-239.
28. Abou-Alfa GK GB, Chou JF, Shia J, Capanu M, Kalin M, et al. (2011) Phase II study of cixutumumab (IMC-A12, NSC742460; C) in hepatocellular carcinoma (HCC). J Clin Oncol 29: (suppl; abstr 4043).
29. Faivre SJ FL, Bouattour M, Bumsel F, Dreyer C, Raymond E, et al. (2011) A phase I study of AVE1642, a human monoclonal antibody-blocking insulin-like growth factor-1 receptor (IGF-1R), given as a single agent and in combination with sorafenib as first-line therapy in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 29: (suppl 4; abstr 270).
30. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, et al. (2012) Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44: 760-764.
31. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, et al. (2012) Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 44: 694-698.
32. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, et al. (2005) Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 11: 4338-4340.
33. Shao YY, Chen CL, Ho MC, Huang CC, Tu HC, et al. (2012) Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma. Anticancer Res 32: 4865-4870.
34. Antoni L, Sodha N, Collins I, Garrett MD, (2007) CHK2 kinase: cancer susceptibility and cancer therapy- two sides of the same coin? Nat Rev Cancer 7: 925-936.
35. Stolz A, Ertych N, Bastians H, (2011) Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability. Clin Cancer Res 17: 401-405.
36. Squatrito M, Holland EC, (2011) DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res 71: 5945-5949.
37. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, et al. (2008) Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 68: 6698-6707.
38. Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoel MJ, Fartoux L, Venot C, et al. (2009) Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 15: 5445-5456.
39. Floc'h N, Kinkade CW, Kobayashi T, Aytes A, Lefebvre C, et al. (2012) Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res 72: 4483-4493.
40. Mazzoletti M, Bortolin F, Brunelli L, Pastorelli R, Di Giandomenico S, et al. (2011) Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res 71: 4573-4584.
41. Boucher J, Macotela Y, Bezy O, Mori MA, Kriauciunas K, et al. (2010) A kinase-independent role for unoccupied insulin and IGF-1 receptors in the control of apoptosis. Sci Signal 3: ra87.
42. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, et al. (2011) Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 30: 2730-2740.